Shape-set textile structure based mechanical thrombectomy systems

Information

  • Patent Grant
  • 9750524
  • Patent Number
    9,750,524
  • Date Filed
    Thursday, October 29, 2015
    8 years ago
  • Date Issued
    Tuesday, September 5, 2017
    7 years ago
Abstract
A biomedical shape-set textile structure based mechanical thrombectomy systems and methods are described. In one of the embodiments, the mechanical thrombectomy device can be customized to the length of the clot in each patient. In one of the embodiments, the mechanical thrombectomy device because of the textile structure has a very low overall profile or thickness that is less than 0.0125 inches (0.317 mm) and therefore can be deployed within microcatheters with inner lumen diameter as small as 0.014 inches (0.355 mm).
Description
FIELD

The present disclosure generally relates to devices, systems, methods for making, and methods for use in thrombectomy. Several embodiments relate to systems and methods for providing novel approaches for stroke treatment.


BACKGROUND

Stroke is the leading cause of long term disability in the United States and the second leading cause of death worldwide with over 4.4 million deaths in a year (1999). There are over 795,000 new strokes every year in the United States. Around 85% of all strokes are acute ischemic strokes caused from a blockage in a blood vessel or a blood clot occluding a blood vessel. In 1996, the FDA approved a thrombolytic drug to dissolve blood clots called recombinant tissue plasminogen activator (r-tpa). Despite practice guidelines from multiple national organizations stating the intravenous r-tpa is the standard of care for patients with acute ischemic stroke within 3 hours from symptom onset, only 3-4% of patients with acute ischemic stroke received this drug in the United States. Unlike intravenous r-tpa, catheter-based therapies for mechanical thrombectomy can be used for up to 8 hours or beyond from acute ischemic stroke symptom onset and could benefit more people. With advances in regional stroke networks, there are more and more stroke patients who are getting access to intra-arterial thrombolysis and therapies, and are as high as 21.6%.


SUMMARY

Blood clots can range from 5 mm to greater than 55 mm. In addition, blood clots can extend from one vessel diameter to another vessel diameter. There is clearly an unmet need currently for a mechanical thrombectomy device that is gentle and safe on the fragile human blood vessels, that can be customized to the length of the clot or clot burden using the same device by the operator, that can be visualized with ease under X-ray fluoroscopy, that can reach the smallest of human blood vessels, that can be compatible with torsional rasping of the clot, and/or have bonding zones or attachment points that are strong even between dissimilar metals or alloys to avoid the risk of any fracture points, as well as have flexible delivery systems that have good proximal support and good distal flexibility. Several embodiments of the invention provide one or more of the advantages above. In some embodiments, all of the advantages above are provided.


In several embodiments, the device is particularly beneficial because it includes one or more of the following advantages: (i) adapted for and gentle on the fragile blood vessels instead of an expansile laser-cut stent based mechanical thrombectomy device; (ii) tapered to mimic the tapering of the human blood vessels thereby allowing for the use of a single tapered device to remove blood clots extending across different tapering blood vessel diameters; (iii) allows for flexibility during deployment and retrieval in tortuous human blood vessels thereby allowing for longer usable lengths of the device; (iv) comprises a long usable length can be customized to the length of the clot or the clot burden without having to use multiple devices to remove the clot in piece meal; (v) a textile structure based mechanical thrombectomy device allows for torsional rasping of the textile structure around the blood clot to entrap the clot and retrieve it; (vi) allows for filtering distal emboli or debris that may be released; (vii) employs processes to bond the textile structure and the delivery system allow for bonding of dissimilar metals or alloys; (viii) comprises an inlay bonding approach of the textile structure with the delivery system, which allows for a low overall profile and outer diameter of the mechanical thrombectomy device in the collapsed configuration to be less than e.g., 0.0125 inches (0.317 mm); (ix) low overall profile and outer diameter of the mechanical thrombectomy device in the collapsed configuration allows for the device to be deployed with a microcatheter that has an inner lumen diameter of e.g., 0.014 inch or greater (0.355 mm); (x) patterns of radio-opaque filaments or wires to achieve maximal radio-opacity and visibility for the operator during X-ray fluoroscopy; (xi) multiple transition points for the laser-cut delivery system or hypotube, which allows for distal flexibility and proximal support as well as supports the ability to perform torsional rasping of the clot; and/or (xii) the laser-cut hypotube with multiple transition points is incorporated as the core braid for the wall of the microcatheter, which allows for distal flexibility and proximal support for allowing the safe and effective deployment of the textile structure based mechanical thrombectomy device.


Various embodiments of the present invention are shown in the figures and described in detail below.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical tapered textile structure.



FIG. 2 is a schematic diagram illustrating the 3D perspective view of one of the embodiments with a spherical tapered textile structure.



FIG. 3 is a schematic diagram illustrating the 2D view of one of the embodiments with an oblong tapered textile structure.



FIG. 4 is a schematic diagram illustrating the 3D perspective view of one of the embodiments with an oblong tapered textile structure.



FIG. 5 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical and oblong interspersed tapered textile structure.



FIG. 6 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical non-tapered textile structure.



FIG. 7 is a schematic diagram illustrating the 2D view of one of the embodiments with an oblong non-tapered textile structure.



FIG. 8 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical and oblong interspersed non-tapered textile structure.



FIG. 9 is a schematic diagram illustrating the 2D view of one of the embodiments with cylindrical wide-mouthed distal tip textile structure.



FIG. 10 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip textile structure.



FIG. 11 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with a spherical or oblong distal filter textile structure.



FIG. 12 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with a spherical distal and proximal filter textile structure.



FIG. 13 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with an oblong distal and proximal filter textile structure.



FIG. 14A is a schematic diagram illustrating the wires positioned on the yarn to develop a biomedical textile structure in one of the embodiments.



FIG. 14B is a schematic diagram illustrating the braid carrier set up mechanism for the position of the wires on the yarn to develop a biomedical textile structure in one of the embodiments.



FIG. 15A is a photograph illustrating the wires being braided into a biomedical textile structure on the yarn in one of the embodiments.



FIG. 15B is a photograph illustrating the wires being knitted into a biomedical textile structure in one of the embodiments.



FIG. 15C is a photograph illustrating the wires being woven into a biomedical textile structure in one of the embodiments.



FIG. 16 is a photograph illustrating the primary tubular shape set textile structure in one of the embodiments.



FIG. 17 is a schematic diagram illustrating the primary shape setting into the necessary geometries needed to develop the shape-set textile structures in one of the embodiments.



FIG. 18 is a photograph illustrating the mandrel used for braiding on the yarn that is then used for primary shape setting into the necessary geometries needed in one of the embodiments.



FIG. 19 is a photograph illustrating secondary shape setting into the necessary geometries needed to develop the shape-set textile structure in one of the embodiments.



FIG. 20 is an X-ray photograph illustrating one of the embodiments where there is grouping of multiple radio-opaque filaments or wires together to form an inter-twining thick band for maximal radio-opacity during fluoroscopy.



FIG. 21 is an X-ray photograph illustrating single filaments inter-twined to provide radio-opacity during fluoroscopy in one of the embodiments.



FIG. 22 is an X-ray photograph illustrating double filaments inter-twined to provide radio-opacity during fluoroscopy in one of the embodiments.



FIG. 23 is a photograph illustrating the need for post-processing of the free end of the textile structure to keep the filaments or wires from fraying in one of the embodiments.



FIG. 24 is a schematic diagram illustrating the appearance of the free end of the textile structure after laser cutting the free end to keep the filaments or wires from fraying in one of the embodiments.



FIG. 25 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and the delivery system using solder in one of the embodiments.



FIG. 26 is a schematic diagram illustrating the overall ratio of the cross-sectional area between the filaments or wires of the textile structure and the bonding agent in one of the embodiments.



FIG. 27A is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and delivery system using epoxy agents in one of the embodiments.



FIG. 27B is a photograph illustrating the inlay bonding approach between the shape-set textile structure and delivery system using epoxy agents in one of the embodiments.



FIG. 28 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and delivery system using a pinched ring as well as a bonding agent in one of the embodiments.



FIG. 29 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and delivery system using a pinched tube as well as a bonding agent in one of the embodiments.



FIG. 30 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure and the distal end of the delivery system using solder in one of the embodiments.



FIG. 31 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure and the distal end of the delivery system using epoxy in one of the embodiments.



FIG. 32 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure and the non-laser cut distal tip of the delivery system using epoxy in one of the embodiments.



FIG. 33 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure and the distal end of the delivery system using epoxy and heat shrink tubing in one of the embodiments.



FIG. 34 is a schematic diagram illustrating the overlay bonding approach between the distal neck of the shape-set textile structure and the distal end of the delivery system using bonding agent in one of the embodiments.



FIG. 35 is a photography illustrating the angled flexible laser-cut hypotube delivery system in one of the embodiments.



FIG. 36 is a schematic diagram illustrating dimensions for laser-cut Pattern A in one of the embodiments.



FIG. 37 is a schematic diagram illustrating dimensions for laser-cut Pattern B in one of the embodiments.



FIG. 38 is a schematic diagram illustrating the directional stagger of laser-cut Pattern A and Pattern B in one of the embodiments.



FIG. 39 is a schematic diagram illustrating the interspersed laser-cut Pattern A and B in one of the embodiments.



FIG. 40 is a schematic diagram illustrating the interspersed laser-cut Pattern A and B with the inter-pattern stagger in one of the embodiments.



FIG. 41 is a schematic diagram illustrating the edges of the kerf in the angled laser-cut delivery system or hypotube are rounded or sharp in one of the embodiments.



FIG. 42 is a schematic diagram illustrating the flexible transition points in the laser-cut pattern of the hypotube in one of the embodiments.



FIG. 43 is a photograph illustrating the degree of angled laser-cut and the degree of uncut in the angled laser-cut delivery system or hypotube in one of the embodiments.



FIG. 44 is a schematic diagram illustrating the horizontal laser-cut delivery system in one of the embodiments.



FIG. 45 is a schematic diagram illustrating the edges of the kerf in the horizontal laser-cut delivery system or hypotube are rounded or sharp in one of the embodiments.



FIG. 46 is a photograph illustrating the degree of horizontal laser-cut and the degree of uncut in the horizontal laser-cut delivery system or hypotube in one of the embodiments.



FIG. 47 is a schematic diagram illustrating a hybrid delivery system with the filaments or wires that are braided together like a hypotube in one of the embodiments.



FIG. 48 is a schematic diagram illustrating a thrombus or blood clot in the right middle cerebral artery causing an acute ischemic stroke noted during angiography with a guide catheter or a shuttle or a balloon guide catheter positioned in the right internal carotid artery in one of the embodiments.



FIG. 49 is a schematic diagram illustrating a standard microcatheter being advanced across the thrombus or blood clot in the right middle cerebral artery over a microwire in one of the embodiments.



FIG. 50 is a photograph illustrating the shape-set textile structure based mechanical thrombectomy device in one of the embodiments.





DRAWINGS—REFERENCE NUMERALS

Part numbers for the Figures are listed below













Part



Number
Description
















1
Distal Tip


5
Extra small spherical bulbs (d = 3 mm)


10
Small spherical bulbs (d = 3.5 mm)


15
Medium spherical bulbs (d = 4 mm)


20
Large spherical bulbs (d = 4.5 mm)


25
Proximal Marker band


30
Delivery System/Hypotube


35
Extra small vessel segment


40
Small vessel segment


45
Medium vessel segment


50
Large vessel segment


55
Usable length


60
Proximal marker to distal tip length


65
Narrow Distal Neck


70
Wide Distal Neck


75
Extra Small oblong bulbs


80
Small oblong bulbs


85
Medium oblong bulbs


90
Large oblong bulbs


95
Narrow neck between bulbs


100
Non-tapered spherical bulbs (diameter = 1-30 mm)


105
Non-tapered oblong bulbs (diameter = 1-30 mm)


110
Proximal neck


115
Cylindrical shape-set structure


120
Distal marker band


125
Distal spherical filter (diameter = 1-30 mm)


130
Proximal spherical filter (diameter = 1-30 mm)


135
Distal oblong filter (diameter = 1-30 mm)


140
Proximal oblong filter (diameter = 1-30 mm)


145
Yarn Wheel


150
Spindle


155
Filament of textile structure


160
Preform point


165
Textile structure


170
Direction of rotation of yarn wheel


175
Cylindrical mandrel


190
Laser cut free end of the textile structure


195
Lead free solder with flux 2 or 3


200
Epoxy glue


205
Any type of bonding agent - solder, epoxy glue etc.


210
Pinched Ring


215
Pinched cylinder


220
Heat Shrink PET tube


225
Overlay bonding zone


230
Uncut bonding zone


235
Hypotube through cross-section of textile structure


240
Distal to distal overlay bonding zone


245
Kerf Width


250
Strut Width


251
Strut Width 2


252
Strut Width 3


253
Strut Width 4


255
Laser cut length


260
Anchor point distance (gap between 2 kerfs on same row)


265
Delivery system wall thickness


270
Step 1 of diagonal stagger distance between two rows of laser



cuts of the same pattern


275
Step 2 of diagonal stagger distance between two rows of laser



cuts of the same pattern


280
Direction of pattern A laser cut


285
Direction of pattern B laser cut


295
Length of delivery system


300
Inner diameter circumference of delivery system


305
Outer diameter circumference of delivery system


310
Direction of folding delivery system (Compressing expanded



view into cylindrical view of delivery system)


315
Inter-pattern stagger distance between rows


320
Laser cut pattern A


330
Laser cut pattern A and B interspersed


335
Rounded kerf edge


340
Square or sharp kerf edge


345
wires of delivery system


350
Bonding zone of textile structure to delivery system


355
bonding agent for filaments of delivery system


360
Extra small pitches (Kerf width plus strut width)


365
Small pitches (Kerf width plus strut width)


370
Medium pitches (Kerf width plus strut width)


375
Large pitches (Kerf width plus strut width)


580
Guide catheter


590
Microcatheter


600
Microwire


650
Blood clot or Clot burden









DETAILED DESCRIPTION


FIG. 1 is a schematic diagram that illustrates a two-dimensional front view of one of the embodiments with a spherical tapered textile structure. It has three components in one of the embodiments: a shape-set textile structure, a bonding zone at the region of the proximal marker band, and a delivery system or hypotube.


The shape-set tapered textile structure in several embodiments has a distal tip, that in the expanded configuration has an outer diameter of less than e.g., 0.017 inches (0.43 mm) and in the collapsed configuration has an outer diameter of less than e.g., 0.0125 inches (0.317 mm) In several embodiments, the expanded configuration of the tip has a diameter in the range of about 0.35-0.65 mm (e.g., 0.40-0.45 mm) In several embodiments, the collapsed configuration has a diameter in the range of about 0.1-0.34 mm (e.g., 0.25-0.33 mm) In some embodiments, for larger vessels, the expanded configuration has a diameter in the range of about 1-40 mm and a diameter in the range of about 0.5-10 mm in a collapsed configuration. In some embodiments, the ratio of the expanded configuration to the collapsed configuration is 1.2:1-10:1. In several embodiments, the distal neck is narrow and has similar outer diameter in the expanded and collapsed configuration as the distal tip. The distal neck has a length that ranges from about 1-5 mm in one of the embodiments.


In several embodiments, there are a total of 10 spherical bulbs in one of the embodiments with varying diameters in the expanded configuration and in the collapsed configuration has an outer diameter of less than e.g., 0.0125 inches (0.317 mm) In several embodiments, the expanded configuration of the bulbs has a diameter in the range of about 1-6 mm (e.g., 3-4.5 mm) In several embodiments, the collapsed configuration has a diameter in the range of about 0.1-0.9 mm (e.g., 0.25-0.5 mm) In some embodiments, for larger vessels, the expanded configuration has a diameter in the range of about 5-40 mm and a diameter in the range of about 0.5-5 mm in a collapsed configuration. In some embodiments, the ratio of the expanded configuration to the collapsed configuration is 1.2:1-10:1.


In some embodiments, the varying outer diameters of the 10 spherical bulbs in the expanded configuration are as follows in one of the embodiments: The distal three extra-small spherical bulbs have an outer diameter (e.g., d=3 mm) in the expanded configuration and corresponds to the extra-small vessel segments such as the M2 segments of the middle cerebral artery, the next three small spherical bulbs have an outer diameter (e.g., d=3.5 mm) in the expanded configuration and corresponds to the smaller vessel segments such as the distal M1 segment of the middle cerebral artery, the next two medium spherical bulbs have an outer diameter (e.g., d=4 mm) in the expanded configuration and corresponds to the medium vessel segments such as the proximal M1 segment of the middle cerebral artery, and the proximal two large spherical bulbs have an outer diameter (d=4.5 mm) in the expanded configuration that corresponds to the large vessel segments such as the distal supra-clinoid segment of the internal carotid artery. This tapered configuration of the shape-set textile structure allows for adequate and safe deployment of the device across blood vessels with multiple diameters. Although specific diameter numbers are provided in this paragraph, other embodiments include diameters that are +/−5, 10, 15, or 20%.


In some embodiments, 10 bulbs are used. However, in other embodiments, 1-9 bulbs or 11-30 (or more) bulbs may be used. In some embodiments, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 bulbs are used. In some conditions, for example in the leg, where clots can be up 20-40 cm, 40-60 bulbs may be used. In some embodiments, 1 bulb is used for every 0.2-5 cm (e.g., about 0.5-2 cm).


In several embodiments, bulbs of various sizes and/or shapes are provided on a single elongate support structure (such as a neck, tube, spindle, spine, rod, backbone, etc.). The elongate support structure may be hollow, filled or partially hollow. The elongate support structure may have a length in the range of about 1-20 cm (e.g., about 4-8 cm, 5-10 cm, etc). In larger vessels (e.g., outside the brain) the length can be about 20-50 cm. The diameter or width of the elongate support structure is in the range of about 0.35-0.65 mm (e.g., 0.40-0.45 mm) in an expanded configuration and in the range of about 0.1-0.34 mm (e.g., 0.25-0.33 mm) in the collapsed configuration. In some embodiments, for larger vessels, the expanded configuration of the elongate support structure has a diameter in the range of about 1-40 mm (e.g., 5-20 mm) and a diameter in the range of about 0.5-10 mm (e.g., 1-2 mm) in a collapsed configuration. Wall thickness of the elongate support structure are, in some embodiments, ranges from about 0.01-4 mm (e.g., about 0.02-1 mm 0.02-0.05 mm, e.g., 0.025 mm) The elongate support structure may be braided, knitted or weaved with two or more strands (e.g., about 12-120 strands, 12-96 strands, 48 strands) in some embodiments. The pattern, in some embodiments, is one-over-one-under-two, one-over-one-under-one, two-over-two-under-two, etc. In some embodiments, the braid angle is in the range of about 45-179 degrees (e.g., about 130-160 degrees, 151 degrees). The picks (or pixels) per inch (PPI) range from about 50-300 PPI (e.g., about 150-190 PPI, e.g., 171 PPI). In some embodiments, increased outward expansile force and/or compression resistance is provided by a higher braid angle and/or higher PPI. In some embodiments, the force/resistance (e.g., radial force) is in a range sufficient to expand a target vessel in the range of about 0%-30%. In some embodiments, the total diameter size of the treatment device is 0.5 mm-1.5 mm greater than the target vessel diameter. In some embodiments, the total diameter size of the treatment device is oversized by 10-50% with respect to the target vessel diameter. The elongate support structure may be made of shape memory alloys (e.g., nickel titanium). In some embodiments, the elongate support structure is about 50-95% (e.g., 75%) nickel titanium and about 5-50% (e.g., 25%) platinum iridium or platinum tungsten or combinations thereof. The radio-opaque portions can be spaced or clustered to increase visibility under x-ray. For example, a thick band pattern may be used which can include 1-12 radio-opaque strands (e.g., filaments, wires, etc.) that are wound adjacently with one another. In several embodiments, the bulbs are integral with the elongate support structure. In other embodiments, the bulbs are coupled (fixably or reversibly coupled) to the elongate support structure.


For example, bulbs size (with respect to the outer diameter in an expanded configuration) is about 0.5-3 mm (e.g., 3 mm), about 3.1-3.9 mm (e.g., 3.5 mm), about 4-4.4 mm (e.g., 4 mm), and about 4.5-7.5 mm (e.g., 4.5 mm) are provided. In some embodiments, the bulbs are sized in the range of about 1 mm-80 mm (e.g., 2 mm-12 mm) Bulbs in range of 4-10 mm may be particular beneficial for larger clots and/or vessels (e.g., in the leg). The sizes above are reduced by 1.3-10 times in the collapsed configuration. In some embodiments, the collapsed configuration of the bulbs is about 50-80% of the inner diameter of the delivery catheter (e.g., microcatheter). In some embodiments, each consecutive bulb is larger than the other. In other embodiments, two sizes are used in an alternate pattern. In yet other embodiments, three or more sizes are used in a series, and each series is repeated two, three, four, five, six, seven, or more times. As an example, if a series of three sizes is alternated, twenty-one bulbs are used. In some embodiments, larger bulbs may be used at the ends, while smaller bulbs are used in the middle. Bulbs may be smaller at the ends and larger in the middle.


Various bulb shapes may be used according to several embodiments, including spherical, oblong, egg, and elliptical (e.g., with respect to top view, side-view and/or cross-section). Square, rectangular and diamond-shapes (e.g., with respect to top view, side-view and/or cross-section) are used in some embodiments. Spiral, twisted, or helical bulbs are provided in some embodiments. For example, sphere-like bulbs and oblong bulbs may be used in a single strand. In some embodiments, shapes are alternated. In yet other embodiments, three or more shapes are used in a series, and each series is repeated two, three, four, five, six, seven, or more times. In some embodiments, bulbs of a first shape may be used at the ends, while bulbs of a second shape are used in the middle. Bulbs may be a first shape at the ends and a second shape in the middle, or vice versa.


The positioning of the bulbs may be beneficial for certain vessel sizes and/or clot locations, material, and/or sizes. Bulbs may be touching (e.g., contiguous) or non-touching. A single strand may include bulbs that are both touching and non-touching. In several embodiments, a strand includes bulbs that are all non-touching and/or are spaced apart by one or more spacers. These spacers may be of the same or different material than the bulbs. The spacers may also be shaped differently than the bulbs. The spacers may comprise, be embedded with or coated by markers or other visualization aids (such as radio-opaque portions).


The bulbs may be separated by distances of about 0.1 to 50 mm, including, but not limited to, about 0.5-1, 1-2, 2-3, 3-4, 4-5, 5-8, 8-10, 10-12, 12-15, 15-25, 25-35, and 35-50 mm apart, including overlapping ranges thereof. The spaces between all the bulbs in one strand may be constant. Alternatively, the spacing between two or more (or all) of the bulbs may be different. In some embodiments, some bulbs are spaced the same distance from one another, while other bulbs have different spacing.



FIG. 2 is a schematic diagram illustrating the 3D perspective view of one of the embodiments with a spherical tapered textile structure.



FIG. 3 is a schematic diagram illustrating the 2D view of one of the embodiments with an oblong tapered textile structure.



FIG. 4 is a schematic diagram illustrating the 3D perspective view of one of the embodiments with an oblong tapered textile structure.



FIG. 5 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical and oblong interspersed tapered textile structure.



FIG. 6 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical non-tapered textile structure.



FIG. 7 is a schematic diagram illustrating the 2D view of one of the embodiments with an oblong non-tapered textile structure.



FIG. 8 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical and oblong interspersed non-tapered textile structure.



FIG. 9 is a schematic diagram illustrating the 2D view of one of the embodiments with cylindrical wide-mouthed distal tip textile structure.



FIG. 10 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip textile structure.



FIG. 11 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with a spherical or oblong distal filter textile structure.



FIG. 12 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with a spherical distal and proximal filter textile structure.



FIG. 13 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with an oblong distal and proximal filter textile structure.



FIG. 14A is a schematic diagram illustrating the wires positioned on the yarn to develop a biomedical textile structure in one of the embodiments.



FIG. 14B is a schematic diagram illustrating the braid carrier set up mechanism for the position of the wires on the yarn to develop a biomedical textile structure in one of the embodiments.



FIG. 15A is a photograph illustrating the wires being braided into a biomedical textile structure on the yarn in one of the embodiments. FIG. 15B is a photograph illustrating the wires being knitted into a biomedical textile structure in one of the embodiments. FIG. 15C is a photograph illustrating the wires being woven into a biomedical textile structure in one of the embodiments.



FIG. 16 is a photograph illustrating the primary tubular shape set textile structure in one of the embodiments.



FIG. 17 is a schematic diagram illustrating the primary shape setting into the necessary geometries needed to develop the shape-set textile structures in one of the embodiments.



FIG. 18 is a photograph illustrating the mandrel used for braiding on the yarn that is then used for primary shape setting into the necessary geometries needed in one of the embodiments.



FIG. 19 is a photograph illustrating secondary shape setting into the necessary geometries needed to develop the shape-set textile structure in one of the embodiments.



FIG. 20 is an X-ray photograph illustrating one of the embodiments where there is grouping of multiple radio-opaque filaments or wires together to form an inter-twining thick band for maximal radio-opacity during fluoroscopy.


Radio-opaque materials, metals or alloys, including but not limited to iridium, platinum, tantalum, gold, palladium, tungsten, tin, silver, titanium, nickel, zirconium, rhenium, bismuth, molybdenum, or combinations of the above etc. to enable visibility during interventional procedures.



FIG. 21 is an X-ray photograph illustrating single filaments inter-twined to provide radio-opacity during fluoroscopy in one of the embodiments.



FIG. 22 is an X-ray photograph illustrating double filaments inter-twined to provide radio-opacity during fluoroscopy in one of the embodiments.



FIG. 23 is a photograph illustrating the need for post-processing of the free end of the textile structure to keep the filaments or wires from fraying in one of the embodiments. Post-processing of the free end of the textile structure (e.g., the elongate support structure and the bulbs) in some of the embodiments includes dip coating, spray coating, sandwich welding the free end using radio-opaque marker bands. Radio-opaque marker band materials, metals or alloys, including but not limited to iridium, platinum, tantalum, gold, palladium, tungsten, tin, silver, titanium, nickel, zirconium, rhenium, bismuth, molybdenum, or combinations of the above etc. to enable visibility during interventional procedures. In some of the embodiments, radio-opaque marker bands can be sandwich welded to the free end of the textile structure (e.g., the elongate support structure and the bulbs), butt welded to the distal end of the delivery system/hypotube, bonded or soldered to the delivery system or hypotube at regular intervals or laser welded into the kerfs created in the laser cut pattern at regular intervals to help measure a clot length, such radio-opaque markers at regular intervals may be separated by distances of about 0.1 to 50 mm, including, but not limited to, about 0.5-1, 1-2, 2-3, 3-4, 4-5, 5-8, 8-10, 10-12, 12-15, 15-25, 25-35, and 35-50 mm apart, including overlapping ranges thereof.


The dip coating or spray coating may comprise a biomedical polymer, e.g., silicone, polyurethane, polyethylene (Rexell™ made by Huntsman), polypropylene, polyester (Hytril™ made by Dupont), poly tetra fluoro-ethylene (PTFE), polyvinyl chloride (PVC), polyamides (Durethan™ made by Bayer), polycarbonate (Corethane™ made by Corvita Corp), or polyethylene-terephthalate. The dip coating or spray coating may further comprise a radio-opaque material, e.g., particles of tantalum, particles of gold, other radio-opaque agents, e.g., barium sulfate, tungsten powder, bismuth subcarbonate, bismuth oxychloride, iodine containing agents such as iohexol (Omnipaque™ Amersham Health).



FIG. 24 is a schematic diagram illustrating the appearance of the free end of the textile structure (e.g., the elongate support structure and the bulbs) after laser cutting the free end to keep the filaments or wires from fraying in one of the embodiments.



FIG. 25 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using solder in one of the embodiments. The solder may be a silver-based lead free solder in some embodiments. The shape-set textile structure may be substantially or fully oxide free when bonding the shape-set textile structure to the delivery system when using such solder.



FIG. 26 is a schematic diagram illustrating the overall ratio of the cross-sectional area between the filaments or wires of the textile structure (e.g., the elongate support structure and the bulbs) and the bonding agent in one of the embodiments.



FIG. 27A is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and delivery system using epoxy agents in one of the embodiments. FIG. 27B is a photograph illustrating the inlay bonding approach between the shape-set textile structure and delivery system using epoxy agents in one of the embodiments.



FIG. 28 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure (e.g., the elongate support structure and the bulbs) and delivery system using a pinched ring as well as a bonding agent in one of the embodiments.



FIG. 29 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure (e.g., the elongate support structure and the bulbs) and delivery system (e.g., a hypotube, wire or multi-filament hybrid) using a pinched tube as well as a bonding agent in one of the embodiments. In some of the embodiments, inlay bonding approach includes laser welding, laser butt welding, laser rivet welding, and mechanical crimping of a flared distal end of the hypotube on the inlayed proximal neck of the textile structure (e.g., the elongate support structure and the bulbs).



FIG. 30 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the distal end of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using solder in one of the embodiments.



FIG. 31 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the distal end of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using epoxy in one of the embodiments.



FIG. 32 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the non-laser cut distal tip of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using epoxy in one of the embodiments.



FIG. 33 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the distal end of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using epoxy and heat shrink tubing in one of the embodiments.



FIG. 34 is a schematic diagram illustrating the overlay bonding approach between the distal neck of the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the distal end of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using bonding agent in one of the embodiments. In some of the embodiments, overlay bonding approach includes laser welding, laser butt welding, laser rivet welding, and mechanical crimping of a flared distal end of the hypotube on the inlayed proximal neck of the textile structure (e.g., the elongate support structure and the bulbs).



FIG. 35 is a photography illustrating the angled flexible laser-cut hypotube delivery system in one of the embodiments.


Various components (e.g., the elongate support structure, the bulbs, the sheath or the delivery system such as the hypotube) may be made up of materials that are biocompatible or surface treated to produce biocompatibility. Suitable materials include e.g., platinum, titanium, nickel, chromium, cobalt, tantalum, tungsten, iron, manganese, molybdenum, and alloys thereof including nitinol, chromium cobalt, stainless steel, etc. Suitable materials also include combinations of metals and alloys. Suitable materials also include polymers such as polylactic acid (PLA), polyglycolic acid (PGA), polyclycoloc-lactic acid (PLGA), polycaprolactone (PCL), polyorthoesters, polyanhydrides, and copolymers thereof. In some embodiments, the thrombectomy device is made of nitinol and platinum tungsten.



FIG. 36 is a schematic diagram illustrating dimensions for laser-cut Pattern A in one of the embodiments.



FIG. 37 is a schematic diagram illustrating dimensions for laser-cut Pattern B in one of the embodiments.



FIG. 38 is a schematic diagram illustrating the directional stagger of laser-cut Pattern A and Pattern B in one of the embodiments.



FIG. 39 is a schematic diagram illustrating the interspersed laser-cut Pattern A and B in one of the embodiments.



FIG. 40 is a schematic diagram illustrating the interspersed laser-cut Pattern A and B with the inter-pattern stagger in one of the embodiments.



FIG. 41 is a schematic diagram illustrating the edges of the kerf in the angled laser-cut delivery system or hypotube are rounded or sharp in one of the embodiments.



FIG. 42 is a schematic diagram illustrating the flexible transition points in the laser-cut pattern of the hypotube in one of the embodiments.



FIG. 43 is a photograph illustrating the degree of angled laser-cut and the degree of uncut in the angled laser-cut delivery system or hypotube in one of the embodiments.



FIG. 44 is a schematic diagram illustrating the horizontal laser-cut delivery system in one of the embodiments.



FIG. 45 is a schematic diagram illustrating the edges of the kerf in the horizontal laser-cut delivery system or hypotube are rounded or sharp in one of the embodiments.



FIG. 46 is a photograph illustrating the degree of horizontal laser-cut and the degree of uncut in the horizontal laser-cut delivery system or hypotube in one of the embodiments.



FIG. 47 is a schematic diagram illustrating a hybrid delivery system with the filaments or wires that are braided together like a hypotube in one of the embodiments.



FIG. 48 is a schematic diagram illustrating a thrombus or blood clot in the right middle cerebral artery causing an acute ischemic stroke noted during angiography with a guide catheter or a shuttle or a balloon guide catheter positioned in the right internal carotid artery in one of the embodiments.



FIG. 49 is a schematic diagram illustrating a catheter (e.g., microcatheter) being advanced across the thrombus or blood clot in the right middle cerebral artery over a microwire in one of the embodiments. The microwire is then removed and the mechanical thrombectomy device is advanced through the hub of the microcatheter via an introducer sheath that is protective encasing for the flexible delivery system. In several embodiments, the catheter (e.g., microcatheter) is reinforced with the laser cut hypotube so as to, in one embodiment, inherit the maneuverability advantages of the hypotube (e.g., to facilitate proximal support and distal flexibility). In some embodiments, a catheter with varying pitches is used. For example, the pitch from the distal end to the proximal end varies as follows: about 0.005 inch, 0.01 inch, 0.02 inch, 0.04 inch, 0.08 inch and 0.16 inch. In some embodiments, the pitch from the distal end to the proximal end varies as follows: about 0.005 inch for the distal most 20%, 0.01 inch for the next 15%, 0.02 inch for the next 15%, 0.04 inch for the next 15%, 0.08 inch for the next 15%, and 0.16 inch for the next (or proximal-most) 20%.


The introducer sheath may comprise a biomedical polymer, e.g., silicone, polyurethane, polyethylene (Rexell™ made by Huntsman), polypropylene, polyester (Hytril™ made by Dupont), poly tetra fluoro-ethylene (PTFE), polyvinyl chloride (PVC), polyamides (Durethan™ made by Bayer), polycarbonate (Corethane™ made by Corvita Corp), or polyethylene-terephthalate. Combinations of two or more of these materials may also be used.


The microcatheter may comprise a biomedical polymer, e.g., silicone, polyurethane, polyethylene (Rexell™ made by Huntsman), polypropylene, polyester (Hytril™ made by Dupont), poly tetra fluoro-ethylene (PTFE), polyvinyl chloride (PVC), polyamides (Durethan™ made by Bayer), polycarbonate (Corethane™ made by Corvita Corp), or polyethylene-terephthalate. Combinations of two or more of these materials may also be used.



FIG. 50 is a photograph illustrating the shape-set textile structure based mechanical thrombectomy device in one of the embodiments.


In several embodiments, the devices described herein can be used in the brain. In some embodiments, vasculature in the periphery can be treated. In some embodiments, coronary vessels are treated. Abdominal aorta and branches are treated in several embodiments.


In some embodiments, a subject having a clot is identified. An access catheter is advanced over a guidewire to a vessel proximate or containing the clot. The guidewire may be removed at this stage. A microcatheter is advanced over a microwire, but stop before or at the clot. The microwire then crosses the clot by 0.5-5 mm (e.g., slices through the center of the clot). The microcatheter is then advanced over the microwire to cross the clot. The microwire is then removed or retracted. The thrombectomy device (the elongate support structure with the bulbs bonded to a delivery system, such as a hypotube, wire or multi-filament wire/hypotube device), as disclosed in several embodiments herein is positioned within an introducer sheath, and together are advanced through the hub of the microcatheter. The thrombectomy device is then advanced through the microcatheter, and the introducer sheath is removed. The thrombectomy device is advanced until it is at the tip of the microcatheter (which is beyond the clot). The thrombectomy device is kept in position, and the microcatheter is retracted (e.g., unsleeved, unsheathed) until the thrombectomy device is expanded. The length of retraction is related to length of the clot in one embodiment (e.g., the microcatheter is retracted to or before the proximal end of the clot). The thrombectomy device is torqued (e.g., in a counterclockwise motion) to facilitate torsional rasping (e.g., rotationally scraping), thereby allowing the bulb(s) to entrap the clot, and collect any debris (emboli). The sticky portions of the clot, which can be attached to the endothelium wall, can be removed by the torqueing motion. The non-laser cut braided nature of the bulbs facilaite gentle entrapment of the clot without perforating the blood vessel. In one embodiment, a 360 degree rotation on the proximal end results in a distal rotation that is less than 360 degrees (e.g., 90-180 degrees). In several embodiments, the rotational force from the proximal end to the distal is not 1:1. Instead the ratio is 1:0.75, 1:0.5 or 1:0.25. This non-1:1 ratio, in some embodiments, is beneficial because it provides a gentle rotation that reduces the risk that the blood vessel is rotated, displaced, disrupted or perforated. In several embodiments, if one bulb cannot fully entrap the clot, another bulb (whether it is the same or different in size and/or shape) will be able to further entrap the clot. In some embodiments, the undulations (e.g., the hills and valleys created by the bulbs and support structure) facilitate clot entrapment. Undulation is also provided at a micro level by the braiding pattern. This dual-undulating pattern enhances scraping and entrapment in several embodiments. The clot, once entrapped or captured by the bulbs, can then be removed as the thrombectomy device is removed from the subject. The thrombectomy device is removed as follows in some embodiments: the microcatheter and the delivery system (e.g., hypotube) are retracted into the tip of the guide catheter while negative suction is applied (e.g., with a syringe) at the level of the guide catheter and also while the microcatheter is retracted at a similar rate such that the microcatheter does not generally recapture any expanded portion of the thrombectomy device or expand (or expose) additional portions of the thrombectomy device. In other words, unexpanded bulbs remain unexpanded and expanded bulbs remain expanded until they are retracted into the guide catheter. Suction can be applied for about 5-30 seconds using a 30-90 cc syringe. The steps above need not be performed in the order recited.


The following references are herein incorporated by reference: (1) Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke. 2000; 31:1588-1601; (2) Wolf P A, D'Agostino R B. Epidemiology of Stroke. In: Barnett H J M, Mohr J P, Stein B M, Yatsu F, eds. Stroke: Pathophysiology, Diagnosis, and Management. 3rd ed. New York, N.Y.: Churchill Livingstone; 1998:6-7; (3) Adams H P, Jr., Adams R J, Brott T, del Zoppo G J, Furlan A, Goldstein L B, Grubb R L, Higashida R, Kidwell C, Kwiatkowski T G, Marler J R, Hademenos G J. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003; 34:1056-1083; (4) Rymer M M, Thrutchley D E. Organizing regional networks to increase acute stroke intervention. Neurol Res. 2005; 27:59-16; and (5) Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark W M, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Jama. 1999; 282:2003-2011.


While the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 3 mm” includes “3 mm.”

Claims
  • 1. A thrombectomy device comprising: a plurality of wires woven to form a textile structure having a collapsed configuration and an expanded configuration, the textile structure comprising five to ten self-expanding bulbs in the expanded configuration, at least three of the five to ten self-expanding bulbs having different outer diameters in the expanded configuration, a proximal end bulb of the five to ten self-expanding bulbs larger than at least one middle bulb of the five to ten self-expanding bulbs in the expanded configuration, wherein the plurality of wires comprises shape memory wires and radiopaque wires, and wherein the radiopaque wires are circumferentially clustered to enhance visibility under x-ray; anda delivery system proximal to the textile structure.
  • 2. The device of claim 1, wherein at least one of the self-expanding bulbs has a spherical shape in the expanded configuration.
  • 3. The device of claim 1, wherein the textile structure comprises five said self-expanding bulbs.
  • 4. The device of claim 1, wherein the textile structure comprises six said self-expanding bulbs.
  • 5. The device of claim 1, wherein the textile structure comprises ten said self-expanding bulbs.
  • 6. The device of claim 1, wherein the delivery system comprises a multi-filament hybrid.
  • 7. The device of claim 1, wherein the delivery system comprises a hypotube.
  • 8. The device of claim 1, wherein the delivery system comprises a multi-filament hybrid, wherein the textile structure comprises six said self-expanding bulbs, wherein at least one of the self-expanding bulbs has a spherical shape in the expanded configuration.
  • 9. The device of claim 1, wherein the delivery system comprises a multi-filament hybrid, wherein the textile structure comprises six said self-expanding bulbs, wherein each of the self-expanding bulbs has a spherical shape in the expanded configuration, and wherein the delivery system is coupled to the textile structure using solder comprising radiopaque material.
  • 10. A thrombectomy device comprising: a plurality of wires woven to form a textile structure having a collapsed configuration and an expanded configuration, the textile structure comprising: five to ten self-expanding bulbs in the expanded configuration, the five to ten self-expanding bulbs in the expanded configuration comprising three or more sizes in series and a proximal end bulb of the five to ten self-expanding bulbs larger than at least one middle bulb of the five to ten self-expanding bulbs in the expanded configuration, anda distal neck distal to and radially inward of a distal-most bulb of the self-expanding bulbs; anda delivery system having a distal end overlay bonded to the distal neck.
  • 11. The device of claim 10, wherein the textile structure comprises six said self-expanding bulbs.
  • 12. The device of claim 10, wherein the textile structure comprises ten said self-expanding bulbs.
  • 13. The device of claim 10, wherein the delivery system comprises a multi-filament hybrid.
  • 14. The device of claim 10, wherein the delivery system comprises a multi-filament hybrid, wherein the textile structure comprises six said self-expanding bulbs, wherein at least one of the self-expanding bulbs has a spherical shape in the expanded configuration, and wherein the plurality of wires comprises shape memory wires and radiopaque wires.
  • 15. A thrombectomy device comprising: a plurality of wires woven to form a textile structure having a collapsed configuration and an expanded configuration, the textile structure comprising five to ten self-expanding bulbs in the expanded configuration, the five to ten self-expanding bulbs in the expanded configuration comprising three or more sizes in series and a proximal end bulb of the five to ten self-expanding bulbs larger than at least one middle bulb of the five to ten self-expanding bulbs in the expanded configuration;a delivery system proximal to the textile structure; anda bonding zone where the delivery system is coupled to the textile structure, the bonding zone comprising solder, the solder comprising radiopaque material.
  • 16. The device of claim 15, wherein the textile structure comprises six said self-expanding bulbs.
  • 17. The device of claim 15, wherein the textile structure comprises ten said self-expanding bulbs.
  • 18. The device of claim 15, wherein the delivery system comprises a multi-filament hybrid.
  • 19. The device of claim 15, wherein the delivery system comprises a multi-filament hybrid, wherein the textile structure comprises six said self-expanding bulbs, wherein at least one of the self-expanding bulbs has a spherical shape in the expanded configuration, and wherein the plurality of wires comprises shape memory wires and radiopaque wires.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 14/012,161, filed Aug. 28, 2013, which is a continuation of U.S. patent application Ser. No. 13/952,982, filed Jul. 29, 2013, which claims priority benefit of U.S. Provisional Patent App. No. 61/798,540, filed on Mar. 15, 2013, and U.S. patent application Ser. No. 14/012,161 claims priority benefit of U.S. Provisional Patent App. No. 61/798,540, filed on Mar. 15, 2013. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 C.F.R. §1.57.

US Referenced Citations (734)
Number Name Date Kind
3378282 Demler, Sr. Apr 1968 A
3381114 Nakanuma Apr 1968 A
3596545 Eisenhardt Aug 1971 A
3790744 Bowen Feb 1974 A
4030503 Clark, III Jun 1977 A
4334535 Wilson et al. Jun 1982 A
4560378 Weiland Dec 1985 A
4585436 Davis et al. Apr 1986 A
4778559 McNeilly Oct 1988 A
4964320 Lee, Jr. Oct 1990 A
4984581 Stice Jan 1991 A
4989606 Gehrich et al. Feb 1991 A
5073694 Tessier et al. Dec 1991 A
5108419 Reger et al. Apr 1992 A
5160342 Reger et al. Nov 1992 A
5171383 Sagae et al. Dec 1992 A
5195408 Niehaus Mar 1993 A
5211183 Wilson May 1993 A
5234451 Osypka Aug 1993 A
5265622 Barbere Nov 1993 A
5324276 Rosenberg Jun 1994 A
5370609 Drasler et al. Dec 1994 A
5378234 Hammerslag et al. Jan 1995 A
5383387 Chesterfield et al. Jan 1995 A
5398568 Worrell et al. Mar 1995 A
5423849 Engelson et al. Jun 1995 A
5449372 Schmaltz et al. Sep 1995 A
5484409 Atkinson et al. Jan 1996 A
5522822 Phelps et al. Jun 1996 A
5537696 Chartier Jul 1996 A
5562641 Flomenblit et al. Oct 1996 A
5573520 Schwartz Nov 1996 A
5578074 Mirigian Nov 1996 A
5624508 Flomenblit et al. Apr 1997 A
5645558 Horton Jul 1997 A
5649949 Wallace et al. Jul 1997 A
5690120 Jacobsen Nov 1997 A
5695506 Pike et al. Dec 1997 A
5695507 Auth et al. Dec 1997 A
5697899 Hillman et al. Dec 1997 A
5725552 Kotula et al. Mar 1998 A
5725570 Heath Mar 1998 A
5725572 Lam et al. Mar 1998 A
5733400 Gore et al. Mar 1998 A
5741429 Donadio, III et al. Apr 1998 A
5766219 Horton Jun 1998 A
5772674 Nakhjavan Jun 1998 A
5776162 Kleshinski Jul 1998 A
5780807 Saunders Jul 1998 A
5788558 Klein Aug 1998 A
5792156 Perouse Aug 1998 A
5827304 Hart Oct 1998 A
5836066 Ingram Nov 1998 A
5843051 Adams et al. Dec 1998 A
5843117 Alt et al. Dec 1998 A
5846261 Kotula et al. Dec 1998 A
5849037 Frid Dec 1998 A
5865816 Quinn Feb 1999 A
5868708 Hart et al. Feb 1999 A
5876568 Kindersley Mar 1999 A
5879499 Corvi Mar 1999 A
5882444 Flomenblit et al. Mar 1999 A
5895398 Wensel et al. Apr 1999 A
5895407 Jayaraman Apr 1999 A
5897567 Ressemann et al. Apr 1999 A
5911731 Pham et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935145 Villar et al. Aug 1999 A
5941869 Patterson et al. Aug 1999 A
5944701 Dubrul Aug 1999 A
5951599 McCrory Sep 1999 A
5972019 Engelson et al. Oct 1999 A
5994667 Merdan et al. Nov 1999 A
5996929 Mazodier et al. Dec 1999 A
6019778 Wilson et al. Feb 2000 A
6027863 Donadio, III Feb 2000 A
6030406 Davis et al. Feb 2000 A
6030586 Kuan Feb 2000 A
6066149 Samson et al. May 2000 A
6080170 Nash et al. Jun 2000 A
6090118 McGuckin, Jr. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6102890 Stivland et al. Aug 2000 A
6102933 Lee et al. Aug 2000 A
6107004 Donadio, III Aug 2000 A
6114653 Gustafson Sep 2000 A
6142987 Tsugita Nov 2000 A
6146370 Barbut Nov 2000 A
6146396 Konya et al. Nov 2000 A
6149682 Frid Nov 2000 A
6165199 Barbut Dec 2000 A
6165292 Abrams et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6174330 Stinson Jan 2001 B1
6203561 Ramee et al. Mar 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6227436 Nishikawa et al. May 2001 B1
6237460 Frid May 2001 B1
6241691 Ferrera et al. Jun 2001 B1
6254633 Pinchuk et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6262390 Goland Jul 2001 B1
6281262 Shikinami Aug 2001 B1
6290721 Heath Sep 2001 B1
6344048 Chin et al. Feb 2002 B1
6346117 Greenhalgh Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350271 Kurz et al. Feb 2002 B1
6369355 Saunders Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6383204 Ferrera May 2002 B1
6383205 Samson et al. May 2002 B1
6391044 Yadav et al. May 2002 B1
6395014 Macoviak et al. May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6428558 Jones et al. Aug 2002 B1
6447531 Amplatz Sep 2002 B1
6461370 Gray et al. Oct 2002 B1
6482217 Pintor et al. Nov 2002 B1
6506204 Mazzocchi Jan 2003 B2
6511492 Rosenbluth et al. Jan 2003 B1
6511504 Lau et al. Jan 2003 B1
6514273 Voss et al. Feb 2003 B1
6517888 Weber Feb 2003 B1
6521865 Jones et al. Feb 2003 B1
6530935 Wensel et al. Mar 2003 B2
6530939 Hopkins et al. Mar 2003 B1
6540722 Boyle et al. Apr 2003 B1
6544276 Azizi Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6554848 Boylan et al. Apr 2003 B2
6563080 Shapovalov et al. May 2003 B2
6569183 Kim et al. May 2003 B1
6585755 Jackson et al. Jul 2003 B2
6589263 Hopkins et al. Jul 2003 B1
6589265 Palmer et al. Jul 2003 B1
6602261 Greene, Jr. et al. Aug 2003 B2
6602264 McGuckin, Jr. Aug 2003 B1
6602265 Dubrul et al. Aug 2003 B2
6605074 Zadno-Azizi et al. Aug 2003 B2
6605111 Bose et al. Aug 2003 B2
6610077 Hancock et al. Aug 2003 B1
6612012 Mitelberg et al. Sep 2003 B2
6616676 Bashiri et al. Sep 2003 B2
6626861 Hart et al. Sep 2003 B1
6626936 Stinson Sep 2003 B2
6632241 Hancock et al. Oct 2003 B1
6635070 Leeflang et al. Oct 2003 B2
6652576 Stalker Nov 2003 B1
6656218 Denardo et al. Dec 2003 B1
6666882 Bose et al. Dec 2003 B1
6669721 Bose et al. Dec 2003 B1
6673089 Yassour et al. Jan 2004 B1
6679893 Tran Jan 2004 B1
6682546 Amplatz Jan 2004 B2
6689986 Patel et al. Feb 2004 B2
6692504 Kurz et al. Feb 2004 B2
6695813 Boyle et al. Feb 2004 B1
6696666 Merdan et al. Feb 2004 B2
6696667 Flanagan Feb 2004 B1
6706054 Wessman et al. Mar 2004 B2
6710285 Brown et al. Mar 2004 B2
6712835 Mazzocchi et al. Mar 2004 B2
6719934 Stinson Apr 2004 B2
6740112 Yodfat et al. May 2004 B2
6749560 Konstorum et al. Jun 2004 B1
6749619 Ouriel et al. Jun 2004 B2
6773448 Kusleika et al. Aug 2004 B2
6777647 Messal et al. Aug 2004 B1
6818063 Kerrigan Nov 2004 B1
6837901 Rabkin et al. Jan 2005 B2
6840950 Stanford et al. Jan 2005 B2
6843798 Kusleika et al. Jan 2005 B2
6844603 Georgakos et al. Jan 2005 B2
6849081 Sepetka et al. Feb 2005 B2
6855153 Saadat Feb 2005 B2
6855154 Abdel-Gawwad Feb 2005 B2
6855909 Patel et al. Feb 2005 B2
6860893 Wallace et al. Mar 2005 B2
6861615 Wojcik et al. Mar 2005 B2
6862794 Hopkins Mar 2005 B2
6866680 Yassour et al. Mar 2005 B2
6867389 Shapovalov et al. Mar 2005 B2
6878163 Denardo et al. Apr 2005 B2
6913618 Denardo et al. Jul 2005 B2
6920677 Dolan et al. Jul 2005 B2
6927359 Kleine et al. Aug 2005 B2
6932828 Bonnette et al. Aug 2005 B2
6949103 Mazzocchi et al. Sep 2005 B2
6953472 Palmer et al. Oct 2005 B2
6964670 Shah et al. Nov 2005 B1
6977355 Duley et al. Dec 2005 B2
6989019 Mazzocchi et al. Jan 2006 B2
7004954 Voss et al. Feb 2006 B1
7018401 Hyodoh et al. Mar 2006 B1
7029494 Soun et al. Apr 2006 B2
7033375 Mazzocchi et al. Apr 2006 B2
7037316 McGuckin, Jr. et al. May 2006 B2
7038334 Botos et al. May 2006 B2
7048752 Mazzocchi et al. May 2006 B2
7083640 Lombardi et al. Aug 2006 B2
7090688 Nishtala et al. Aug 2006 B2
7093416 Johnson et al. Aug 2006 B2
7093527 Rapaport et al. Aug 2006 B2
7105003 Hiltebrandt Sep 2006 B2
7118539 Vrba et al. Oct 2006 B2
7125414 Blackledge et al. Oct 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7128752 Bales Oct 2006 B2
7131986 Sirhan et al. Nov 2006 B2
7135039 De Scheerder et al. Nov 2006 B2
7152605 Khairkhahan et al. Dec 2006 B2
7172614 Boyle et al. Feb 2007 B2
7179273 Palmer et al. Feb 2007 B1
7211109 Thompson May 2007 B2
7220269 Ansel et al. May 2007 B1
7220271 Clubb et al. May 2007 B2
7252680 Freitag Aug 2007 B2
7300429 Fitzgerald et al. Nov 2007 B2
7306618 Demond et al. Dec 2007 B2
7306624 Yodfat et al. Dec 2007 B2
7323001 Clubb et al. Jan 2008 B2
7344546 Wulfman et al. Mar 2008 B2
7367985 Mazzocchi et al. May 2008 B2
7367986 Mazzocchi et al. May 2008 B2
7371250 Mazzocchi et al. May 2008 B2
7374564 Brown May 2008 B2
7381198 Noriega et al. Jun 2008 B2
7404820 Mazzocchi et al. Jul 2008 B2
7410491 Hopkins et al. Aug 2008 B2
7410492 Mazzocchi et al. Aug 2008 B2
7410602 Davey et al. Aug 2008 B2
7442200 Mazzocchi et al. Oct 2008 B2
7462192 Norton et al. Dec 2008 B2
7476034 Shedlov et al. Jan 2009 B2
7537600 Eskuri May 2009 B2
7556635 Mazzocchi et al. Jul 2009 B2
7556636 Mazzocchi et al. Jul 2009 B2
7566338 Mazzocchi et al. Jul 2009 B2
7572273 Mazzocchi et al. Aug 2009 B2
7572290 Yodfat et al. Aug 2009 B2
7582101 Jones et al. Sep 2009 B2
7588597 Frid Sep 2009 B2
7618434 Santra et al. Nov 2009 B2
7621870 Berrada et al. Nov 2009 B2
7622070 Atladottir et al. Nov 2009 B2
7645261 Hinchliffe Jan 2010 B2
7651514 Salahieh et al. Jan 2010 B2
7669799 Elzey et al. Mar 2010 B2
7670355 Mazzocchi et al. Mar 2010 B2
7670356 Mazzocchi et al. Mar 2010 B2
7678130 Mazzocchi et al. Mar 2010 B2
7686815 Mazzocchi et al. Mar 2010 B2
7717935 Tsugita et al. May 2010 B2
7735493 van der Burg et al. Jun 2010 B2
7763011 Ortiz et al. Jul 2010 B2
7780646 Farnholtz Aug 2010 B2
7786406 Flanagan Aug 2010 B2
7798992 Ortiz Sep 2010 B2
7828790 Griffin Nov 2010 B2
7828815 Mazzocchi et al. Nov 2010 B2
7828816 Mazzocchi et al. Nov 2010 B2
7837726 Von Oepen et al. Nov 2010 B2
7846175 Bonnette et al. Dec 2010 B2
7857844 Norton et al. Dec 2010 B2
7862577 Gray et al. Jan 2011 B2
7875050 Samson et al. Jan 2011 B2
7879062 Galdonik et al. Feb 2011 B2
7892188 Walker et al. Feb 2011 B2
7909801 Hinchliffe Mar 2011 B2
7914549 Morsi Mar 2011 B2
7922732 Mazzocchi et al. Apr 2011 B2
7931664 Gray et al. Apr 2011 B2
7932479 Bialas et al. Apr 2011 B2
7942925 Yodfat et al. May 2011 B2
7955345 Kucharczyk et al. Jun 2011 B2
7955449 Prokoshkin et al. Jun 2011 B2
7971333 Gale et al. Jul 2011 B2
7989042 Obara et al. Aug 2011 B2
7993302 Hebert et al. Aug 2011 B2
7993363 Demond et al. Aug 2011 B2
7993364 Morsi Aug 2011 B2
7996993 Gray et al. Aug 2011 B2
7998163 Salahieh et al. Aug 2011 B2
8003157 Andreacchi et al. Aug 2011 B2
8021379 Thompson et al. Sep 2011 B2
8021380 Thompson et al. Sep 2011 B2
8043326 Hancock et al. Oct 2011 B2
8044322 Merdan Oct 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8057497 Raju et al. Nov 2011 B1
8070769 Broome Dec 2011 B2
8088140 Ferrera et al. Jan 2012 B2
8092483 Gladonik et al. Jan 2012 B2
8092486 Berrada et al. Jan 2012 B2
8092508 Leynov et al. Jan 2012 B2
8142456 Rosqueta et al. Mar 2012 B2
8147534 Berez et al. Apr 2012 B2
8152833 Zaver et al. Apr 2012 B2
8157833 Au et al. Apr 2012 B2
8192484 Frid Jun 2012 B2
8197493 Ferrera et al. Jun 2012 B2
8217303 Baxter et al. Jul 2012 B2
8231651 Tsugita Jul 2012 B2
8235047 Swann et al. Aug 2012 B2
8236042 Berez et al. Aug 2012 B2
8252010 Raju et al. Aug 2012 B1
8252016 Anwar Aug 2012 B2
8257421 Berez et al. Sep 2012 B2
8261648 Marchand et al. Sep 2012 B1
8267985 Garcia et al. Sep 2012 B2
8267986 Berez et al. Sep 2012 B2
8273101 Garcia et al. Sep 2012 B2
8278593 Bialas et al. Oct 2012 B2
8292914 Morsi Oct 2012 B2
8308712 Provost et al. Nov 2012 B2
RE43882 Hopkins et al. Dec 2012 E
8333796 Tompkins et al. Dec 2012 B2
8333897 Bialas et al. Dec 2012 B2
8361095 Osborne Jan 2013 B2
8361138 Adams Jan 2013 B2
8394119 Zaver et al. Mar 2013 B2
8398670 Amplatz et al. Mar 2013 B2
8398701 Berez et al. Mar 2013 B2
8409114 Parins Apr 2013 B2
8409267 Berez et al. Apr 2013 B2
8409269 Berez et al. Apr 2013 B2
8409270 Clerc et al. Apr 2013 B2
8419658 Eskuri Apr 2013 B2
8419787 Yodfat et al. Apr 2013 B2
8435218 Hinchliffe May 2013 B2
8444668 Jones et al. May 2013 B2
8468678 Salahieh et al. Jun 2013 B2
8475487 Bonnette et al. Jul 2013 B2
8486104 Samson et al. Jul 2013 B2
8486105 Demond et al. Jul 2013 B2
8500788 Berez et al. Aug 2013 B2
8529614 Berez et al. Sep 2013 B2
8585713 Ferrera et al. Nov 2013 B2
8603132 Anwar Dec 2013 B2
8617201 Hopkins et al. Dec 2013 B2
8617234 Garcia et al. Dec 2013 B2
8623067 Berez et al. Jan 2014 B2
8623071 Lundkvist et al. Jan 2014 B2
8628564 Berez et al. Jan 2014 B2
8663273 Khairkhahan et al. Mar 2014 B2
8671815 Hancock et al. Mar 2014 B2
8679150 Janardhan et al. Mar 2014 B1
8690907 Janardhan et al. Apr 2014 B1
8696621 Gunday et al. Apr 2014 B2
8715314 Janardhan et al. May 2014 B1
8715315 Janardhan et al. May 2014 B1
8715316 Janardhan et al. May 2014 B1
8715317 Janardhan et al. May 2014 B1
8715338 Frid May 2014 B2
8721676 Janardhan et al. May 2014 B1
8721677 Janardhan et al. May 2014 B1
8728116 Janardhan et al. May 2014 B1
8728117 Janardhan et al. May 2014 B1
8733618 Janardhan et al. May 2014 B1
8735777 Janardhan et al. May 2014 B1
8747432 Janardhan et al. Jun 2014 B1
8753371 Janardhan et al. Jun 2014 B1
8758424 Sacher et al. Jun 2014 B2
8764787 Ren Jul 2014 B2
8771299 Diamant et al. Jul 2014 B2
8783151 Janardhan et al. Jul 2014 B1
8784434 Rosenbluth et al. Jul 2014 B2
8784446 Janardhan et al. Jul 2014 B1
8789452 Janardhan et al. Jul 2014 B1
8790299 Gunday et al. Jul 2014 B2
8790365 Janardhan et al. Jul 2014 B1
8795305 Martin et al. Aug 2014 B2
8795330 Janardhan et al. Aug 2014 B1
8801748 Martin Aug 2014 B2
8803030 Janardhan et al. Aug 2014 B1
8813625 Janardhan et al. Aug 2014 B1
8816247 Janardhan et al. Aug 2014 B1
8828045 Janardhan et al. Sep 2014 B1
8845678 Janardhan et al. Sep 2014 B1
8845679 Janardhan et al. Sep 2014 B1
8852227 Janardhan et al. Oct 2014 B1
8859934 Janardhan et al. Oct 2014 B1
8863631 Janardhan et al. Oct 2014 B1
8866049 Janardhan et al. Oct 2014 B1
8869670 Janardhan et al. Oct 2014 B1
8870901 Janardhan et al. Oct 2014 B1
8870910 Janardhan et al. Oct 2014 B1
8872068 Janardhan et al. Oct 2014 B1
8874434 Collobert et al. Oct 2014 B2
8882797 Janardhan et al. Nov 2014 B2
8895891 Janardhan et al. Nov 2014 B2
8904914 Janardhan et al. Dec 2014 B2
8906057 Connor et al. Dec 2014 B2
8910555 Janardhan et al. Dec 2014 B2
8932320 Janardhan et al. Jan 2015 B1
8932321 Janardhan et al. Jan 2015 B1
8968330 Rosenbluth et al. Mar 2015 B2
8974512 Aboytes et al. Mar 2015 B2
8992553 Diamant et al. Mar 2015 B2
8998947 Aboytes et al. Apr 2015 B2
9034007 Janardhan May 2015 B2
9132000 Vantassel et al. Sep 2015 B2
9179931 Janardhan et al. Nov 2015 B2
9179995 Janardhan et al. Nov 2015 B2
9198687 Fulkerson et al. Dec 2015 B2
9211132 Bowman Dec 2015 B2
9211396 Aboytes Dec 2015 B2
9220522 Fulkerson et al. Dec 2015 B2
9314324 Janardhan et al. Apr 2016 B2
9592068 Janardhan et al. Mar 2017 B2
20010031980 Wensel et al. Oct 2001 A1
20020010487 Evans et al. Jan 2002 A1
20020013548 Hinchliffe Jan 2002 A1
20020026211 Khosravi et al. Feb 2002 A1
20020045916 Gray et al. Apr 2002 A1
20020052638 Zadno-Azizi May 2002 A1
20020082558 Samson et al. Jun 2002 A1
20020091355 Hayden Jul 2002 A1
20020099408 Marks et al. Jul 2002 A1
20020099436 Thornton et al. Jul 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020133111 Shadduck Sep 2002 A1
20020143349 Gifford, III et al. Oct 2002 A1
20020161395 Douk Oct 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20020193866 Saunders Dec 2002 A1
20020194670 Hashemi Dec 2002 A1
20020198550 Nash et al. Dec 2002 A1
20020198589 Leong Dec 2002 A1
20030004537 Boyle et al. Jan 2003 A1
20030065356 Tsugita et al. Apr 2003 A1
20030078519 Salahieh et al. Apr 2003 A1
20030097094 Ouriel et al. May 2003 A1
20030097710 Adrian May 2003 A1
20030100945 Yodfat et al. May 2003 A1
20030114919 McQuiston et al. Jun 2003 A1
20030135265 Stinson Jul 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030225448 Gerberding Dec 2003 A1
20030226833 Shapovalov et al. Dec 2003 A1
20040004061 Merdan Jan 2004 A1
20040004063 Merdan Jan 2004 A1
20040024416 Yodfat et al. Feb 2004 A1
20040039435 Hancock et al. Feb 2004 A1
20040044391 Porter Mar 2004 A1
20040073293 Thompson Apr 2004 A1
20040073300 Chouinard et al. Apr 2004 A1
20040088037 Machreiner et al. May 2004 A1
20040089643 Jones et al. May 2004 A1
20040093015 Ogle May 2004 A1
20040098023 Lee et al. May 2004 A1
20040098033 Leeflang et al. May 2004 A1
20040118902 Adams Jun 2004 A1
20040148007 Jackson et al. Jul 2004 A1
20040167613 Yodfat et al. Aug 2004 A1
20040168298 Dolan et al. Sep 2004 A1
20040182451 Poirier Sep 2004 A1
20040193140 Griffin et al. Sep 2004 A1
20040204737 Boismier et al. Oct 2004 A1
20040220610 Kreidler et al. Nov 2004 A1
20040225186 Horne, Jr. et al. Nov 2004 A1
20040236412 Brar et al. Nov 2004 A1
20050015110 Fogarty et al. Jan 2005 A1
20050021075 Bonnette et al. Jan 2005 A1
20050035101 Jones et al. Feb 2005 A1
20050050624 Pangramuyen Mar 2005 A1
20050120471 Lim Jun 2005 A1
20050124969 Fitzgerald et al. Jun 2005 A1
20050131522 Stinson et al. Jun 2005 A1
20050133486 Baker et al. Jun 2005 A1
20050149108 Cox Jul 2005 A1
20050192624 Mazzocchi et al. Sep 2005 A1
20050203553 Maschke Sep 2005 A1
20050228417 Teitelbaum et al. Oct 2005 A1
20050234474 DeMello et al. Oct 2005 A1
20050236911 Botos et al. Oct 2005 A1
20050251200 Porter Nov 2005 A1
20050256563 Clerc et al. Nov 2005 A1
20050267510 Razack Dec 2005 A1
20050277975 Saadat et al. Dec 2005 A1
20050283166 Greenhalgh Dec 2005 A1
20050283186 Berrada et al. Dec 2005 A1
20060004346 Begg Jan 2006 A1
20060009799 Kleshinski et al. Jan 2006 A1
20060020286 Niermann Jan 2006 A1
20060030878 Anderson et al. Feb 2006 A1
20060047286 West Mar 2006 A1
20060070516 McCullagh et al. Apr 2006 A1
20060100687 Fahey et al. May 2006 A1
20060116712 Sepetka et al. Jun 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060122687 Bassler et al. Jun 2006 A1
20060136043 Cully et al. Jun 2006 A1
20060155305 Freudenthal et al. Jul 2006 A1
20060161198 Sakai et al. Jul 2006 A1
20060161253 Lesh Jul 2006 A1
20060206143 West Sep 2006 A1
20060206196 Porter Sep 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060229638 Abrams et al. Oct 2006 A1
20060229645 Bonnette et al. Oct 2006 A1
20060241739 Besselink et al. Oct 2006 A1
20060264904 Kerby et al. Nov 2006 A1
20060276887 Brady et al. Dec 2006 A1
20060282111 Morsi Dec 2006 A1
20070016233 Ferrera et al. Jan 2007 A1
20070027522 Chang et al. Feb 2007 A1
20070034615 Kleine Feb 2007 A1
20070045255 Kleine et al. Mar 2007 A1
20070060880 Gregorich et al. Mar 2007 A1
20070060942 Zadno-Azizi Mar 2007 A2
20070088383 Pal et al. Apr 2007 A1
20070112381 Figulla et al. May 2007 A1
20070118165 DeMello et al. May 2007 A1
20070135832 Wholey et al. Jun 2007 A1
20070135833 Talpade et al. Jun 2007 A1
20070142903 Dave Jun 2007 A1
20070168019 Amplatz et al. Jul 2007 A1
20070173921 Wholey et al. Jul 2007 A1
20070185500 Martin et al. Aug 2007 A1
20070185501 Martin et al. Aug 2007 A1
20070197103 Martin et al. Aug 2007 A1
20070198029 Martin et al. Aug 2007 A1
20070198030 Martin et al. Aug 2007 A1
20070225749 Martin et al. Sep 2007 A1
20070228023 Kleine et al. Oct 2007 A1
20070233174 Hocking et al. Oct 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070288054 Tanaka et al. Dec 2007 A1
20080027356 Chen et al. Jan 2008 A1
20080033475 Meng Feb 2008 A1
20080045881 Teitelbaum et al. Feb 2008 A1
20080065008 Barbut et al. Mar 2008 A1
20080077119 Snyder et al. Mar 2008 A1
20080097374 Korleski et al. Apr 2008 A1
20080097393 Chen Apr 2008 A1
20080097395 Adams et al. Apr 2008 A1
20080097398 Mitelberg et al. Apr 2008 A1
20080097401 Trapp et al. Apr 2008 A1
20080107641 Kuebler May 2008 A1
20080109063 Hancock et al. May 2008 A1
20080195230 Quijano et al. Aug 2008 A1
20080221601 Huynh et al. Sep 2008 A1
20080228209 DeMello et al. Sep 2008 A1
20080234722 Bonnette et al. Sep 2008 A1
20080262487 Wensel et al. Oct 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20080275464 Abrams et al. Nov 2008 A1
20080275488 Fleming Nov 2008 A1
20080294181 Wensel et al. Nov 2008 A1
20080296274 Bialas et al. Dec 2008 A1
20080300673 Clerc et al. Dec 2008 A1
20080306499 Katoh et al. Dec 2008 A1
20080312681 Ansel et al. Dec 2008 A1
20090024085 To et al. Jan 2009 A1
20090025820 Adams Jan 2009 A1
20090036833 Parins Feb 2009 A1
20090043283 Turnlund et al. Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090076540 Marks et al. Mar 2009 A1
20090082800 Janardhan Mar 2009 A1
20090099647 Glimsdale et al. Apr 2009 A1
20090105737 Fulkerson et al. Apr 2009 A1
20090105748 Fogarty et al. Apr 2009 A1
20090105753 Greenhalgh et al. Apr 2009 A1
20090112251 Qian et al. Apr 2009 A1
20090114626 Oberg May 2009 A1
20090125097 Bruszewski et al. May 2009 A1
20090157048 Sutermeister et al. Jun 2009 A1
20090172935 Anderson et al. Jul 2009 A1
20090188269 Attarwala et al. Jul 2009 A1
20090198269 Hannes et al. Aug 2009 A1
20090208385 Howorth et al. Aug 2009 A1
20090209855 Drilling et al. Aug 2009 A1
20090216326 Hirpara et al. Aug 2009 A1
20090221995 Harlan Sep 2009 A1
20090248071 Saint et al. Oct 2009 A1
20090264985 Bruszewski Oct 2009 A1
20090275974 Marchand et al. Nov 2009 A1
20090287120 Ferren et al. Nov 2009 A1
20090297582 Meyer et al. Dec 2009 A1
20090306702 Miloslavski et al. Dec 2009 A1
20090306762 McCullagh et al. Dec 2009 A1
20090312834 Wood et al. Dec 2009 A1
20090318892 Aboytes et al. Dec 2009 A1
20090318948 Linder Dec 2009 A1
20100010622 Lowe et al. Jan 2010 A1
20100023034 Linder et al. Jan 2010 A1
20100023038 Santra et al. Jan 2010 A1
20100023105 Levy et al. Jan 2010 A1
20100030256 Dubrul et al. Feb 2010 A1
20100049240 Papp Feb 2010 A1
20100069882 Jennings et al. Mar 2010 A1
20100069948 Veznedaroglu et al. Mar 2010 A1
20100087850 Razack Apr 2010 A1
20100102046 Huang et al. Apr 2010 A1
20100114017 Lenker et al. May 2010 A1
20100131000 DeMello et al. May 2010 A1
20100137892 Krolik et al. Jun 2010 A1
20100137899 Razack Jun 2010 A1
20100152834 Hannes et al. Jun 2010 A1
20100191319 Lilburn et al. Jul 2010 A1
20100193485 Anukhin et al. Aug 2010 A1
20100217276 Garrison et al. Aug 2010 A1
20100217303 Goodwin Aug 2010 A1
20100230391 Baxter et al. Sep 2010 A1
20100262221 Schafer et al. Oct 2010 A1
20100268264 Bonnette et al. Oct 2010 A1
20100280592 Shin et al. Nov 2010 A1
20100318097 Ferrera et al. Dec 2010 A1
20110036820 Merdan Feb 2011 A1
20110046719 Frid Feb 2011 A1
20110056350 Gale et al. Mar 2011 A1
20110060359 Hannes et al. Mar 2011 A1
20110060400 Oepen et al. Mar 2011 A1
20110077620 deBeer Mar 2011 A1
20110082493 Samson et al. Apr 2011 A1
20110087147 Garrison et al. Apr 2011 A1
20110094708 Cardone Apr 2011 A1
20110125132 Krolik et al. May 2011 A1
20110125181 Brady et al. May 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110160757 Ferrera et al. Jun 2011 A1
20110160760 Ferrera et al. Jun 2011 A1
20110160761 Ferrera et al. Jun 2011 A1
20110190797 Fulkerson et al. Aug 2011 A1
20110190868 Ducke et al. Aug 2011 A1
20110203446 Dow et al. Aug 2011 A1
20110208227 Becking Aug 2011 A1
20110210108 Bialas et al. Sep 2011 A1
20110213403 Aboytes Sep 2011 A1
20110213407 Morsi Sep 2011 A1
20110238041 Lim et al. Sep 2011 A1
20110264133 Hanlon et al. Oct 2011 A1
20110265943 Rosqueta et al. Nov 2011 A1
20110283871 Adams Nov 2011 A1
20110295359 Clerc et al. Dec 2011 A1
20110307072 Anderson et al. Dec 2011 A1
20110319917 Ferrera et al. Dec 2011 A1
20120016406 Ferrera et al. Jan 2012 A1
20120022579 Fulton Jan 2012 A1
20120029616 Guerriero et al. Feb 2012 A1
20120041460 Ferrera et al. Feb 2012 A1
20120055614 Hancock et al. Mar 2012 A1
20120057813 Von Oepen Mar 2012 A1
20120065660 Ferrera et al. Mar 2012 A1
20120083824 Berrada et al. Apr 2012 A1
20120116443 Ferrera et al. May 2012 A1
20120158124 Zaver et al. Jun 2012 A1
20120164157 Kuebler Jun 2012 A1
20120179192 Fogarty et al. Jul 2012 A1
20120197283 Marchand et al. Aug 2012 A1
20120197285 Martin et al. Aug 2012 A1
20120209312 Aggerholm et al. Aug 2012 A1
20120231414 Johnson Sep 2012 A1
20120232655 Lorrison et al. Sep 2012 A1
20120239066 Levine et al. Sep 2012 A1
20120239074 Aboytes et al. Sep 2012 A1
20120245517 Tegels Sep 2012 A1
20120259404 Tieu et al. Oct 2012 A1
20120265238 Hopkins et al. Oct 2012 A1
20120271337 Figulla et al. Oct 2012 A1
20120271403 Gries Oct 2012 A1
20120273467 Baxter et al. Nov 2012 A1
20120277850 Bertini Nov 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120290067 Cam et al. Nov 2012 A1
20120316598 Becking et al. Dec 2012 A1
20120330347 Becking et al. Dec 2012 A1
20120330350 Jones et al. Dec 2012 A1
20130030460 Marks et al. Jan 2013 A1
20130060323 McHugo Mar 2013 A1
20130066357 Aboytes et al. Mar 2013 A1
20130085515 To et al. Apr 2013 A1
20130090682 Bachman et al. Apr 2013 A1
20130092298 Bregulla et al. Apr 2013 A1
20130096587 Smith et al. Apr 2013 A1
20130116284 Salzman May 2013 A1
20130138136 Beckham et al. May 2013 A1
20130167960 Pethe et al. Jul 2013 A1
20130220610 Mosing et al. Aug 2013 A1
20130240096 Browne et al. Sep 2013 A1
20130261656 Lorenzo Oct 2013 A1
20130289589 Krolik et al. Oct 2013 A1
20130327469 Pingleton et al. Dec 2013 A1
20140005712 Martin Jan 2014 A1
20140046359 Bowman et al. Feb 2014 A1
20140074144 Shrivastava et al. Mar 2014 A1
20140081315 McIntosh et al. Mar 2014 A1
20140121758 Ferrera et al. May 2014 A1
20140128905 Molaei May 2014 A1
20140188208 Hancock et al. Jul 2014 A1
20140200608 Brady et al. Jul 2014 A1
20140214067 Sachar et al. Jul 2014 A1
20140243882 Ma Aug 2014 A1
20140249569 Kusleika Sep 2014 A1
20140276403 Follmer et al. Sep 2014 A1
20140276922 McLain et al. Sep 2014 A1
20140277013 Sepetka et al. Sep 2014 A1
20140277082 Janardhan et al. Sep 2014 A1
20140324091 Rosenbluth et al. Oct 2014 A1
20140330302 Tekulve et al. Nov 2014 A1
20140371839 Henkes et al. Dec 2014 A1
20150005801 Marquis et al. Jan 2015 A1
20150018928 Sachar et al. Jan 2015 A1
20150028005 Janardhan et al. Jan 2015 A1
20150032121 Janardhan et al. Jan 2015 A1
20150032146 Janardhan et al. Jan 2015 A1
20150032147 Janardhan et al. Jan 2015 A1
20150080941 Janardhan et al. Mar 2015 A1
20150196744 Aboytes Jul 2015 A1
20150209050 Aboytes et al. Jul 2015 A1
20150209058 Ferrera et al. Jul 2015 A1
20150216650 Shaltis Aug 2015 A1
20150223829 Aboytes Aug 2015 A1
20150238303 Janardhan Aug 2015 A1
20150250497 Marks et al. Sep 2015 A1
20150265299 Cooper et al. Sep 2015 A1
20150272590 Aboytes et al. Oct 2015 A1
20150297240 Divino et al. Oct 2015 A1
20150305756 Rosenbluth et al. Oct 2015 A1
20150314111 Solar et al. Nov 2015 A1
20150342613 Aboytes et al. Dec 2015 A1
20150352325 Quick Dec 2015 A1
20150360001 Quick Dec 2015 A1
20150374391 Quick et al. Dec 2015 A1
20150374393 Brady et al. Dec 2015 A1
20160045212 Janardhan et al. Feb 2016 A1
20160213459 Janardhan et al. Jul 2016 A1
Foreign Referenced Citations (50)
Number Date Country
0 521 595 Jan 1993 EP
1 210 032 Dec 2003 EP
1 059 890 Dec 2004 EP
1 028 671 Jan 2005 EP
1 026 997 Oct 2005 EP
1 156 757 Dec 2005 EP
1 117 344 Jun 2006 EP
1 676 545 Jul 2006 EP
1 214 016 Jun 2007 EP
1 389 959 Nov 2007 EP
1 028 670 Jan 2008 EP
1 459 703 Jan 2008 EP
1 402 848 Oct 2008 EP
1 482 859 Oct 2008 EP
1 715 795 Dec 2008 EP
1 479 357 May 2009 EP
1 494 619 Aug 2009 EP
1 589 900 Sep 2009 EP
1 681 034 Jan 2010 EP
1 487 526 Sep 2010 EP
1 377 224 May 2011 EP
2 113 224 Jun 2011 EP
1 583 485 Sep 2011 EP
2 301 450 Nov 2011 EP
2 217 315 May 2012 EP
0 851 777 Dec 2012 EP
2 057 967 Jan 2013 EP
1 904 217 Mar 2013 EP
1 706 063 Oct 2013 EP
2 517 658 Dec 2013 EP
0 998 228 Jun 2014 EP
1 981 413 Nov 2014 EP
2 482 913 Nov 2014 EP
2 700 368 Feb 2015 EP
1 483 009 Oct 2015 EP
2 474 277 Oct 2015 EP
1 006 890 Sep 2016 EP
667071 Feb 1952 GB
WO 0160442 Aug 2001 WO
WO 2004093738 Nov 2004 WO
WO 2007011353 Jan 2007 WO
WO 2010014447 Feb 2010 WO
WO 2011119872 Sep 2011 WO
WO 2012011097 Jan 2012 WO
WO 2012110619 Aug 2012 WO
WO 2012120490 Sep 2012 WO
WO 2014127738 Aug 2014 WO
WO 2014141226 Sep 2014 WO
WO 2014154137 Oct 2014 WO
WO 2015138649 Sep 2015 WO
Non-Patent Literature Citations (58)
Entry
US 6,348,062, 02/2002, Hopkins et al. (withdrawn)
6th Annual MedTech Investing Conference, “Venture Capital and Private Equity Investing in Medical Devices and Healthcare Technologies,” May 16-17, 2007.
Abbott Laboratories, “Xact Carotid Stent System, RX ACCULINK Carotid Stent System, 2006 Clinical Update for Physicians”, 2007.
Adams et al., “Guidelines for the Early Management of Patients with Ischemic Stroke: A Scientific Statement from the Stroke Council of the American Stroke Association,” Stroke, 2003, vol. 34, pp. 1056-1083.
Adams et al., “Guidelines for the Early Management of Patients with Ischemic Stroke—2005 Guidelines Update—A Scientific Statement from the Stroke Council of the American Stroke Association,” Stroke, 2005, vol. 36, pp. 916-923.
Alligator Retrieval Device Product Brochure, 2009.
Bose et al., “A Novel, Self-Expanding, Nitinol Stent in Medically Refractory Intracranial Atherosclerotic Stenoses, The Wingspan Study,” http://stroke.ahajournals.org/, American Heart Association, Inc., 2007, pp. 1531-1537.
Boston Scientific, “Excelsior 1018 Microcatheter, for Peak Performance in GDC Delivery,” 2000.
Boston Scientific, “Excelsior 1018 Microcatheter, Neurovascular Access,” 2004.
Boston Scientific, “Excelsior SL-10 Microcatheter, Neurovascular Access,” 2004.
Boston Scientific, “Excelsior SL-10 Microcatheter, The 10 Microcatheter with a 14 Lumen,” 2002.
Boston Scientific, “FilterWire EX, Embolic Protection System, Instruction for Use,” Apr. 2004.
Boston Scientific, “Neuroform2 Microdelivery Stent System, Technical Bulletin No. 1—Parent Vessel Protection,” 2004.
Boston Scientific, “Neuroform2 Microdelivery Stent System, Neurovascular Reconstruction,” 2004.
Boston Scientific, “Neuroform3 Microdelivery Stent System, Confidence Begins with Control,” 2005.
Boston Scientific, “Pre-Shaped Microcatheters, Product Selection Guide,” 2004.
Boston Scientific, “Renegade 18 Microcatheter, Neurovascular Access,” 2004.
Boston Scientific, “Synchro Guidewires, Neurovascular Access,” 2004.
Boston Scientific, “Tracker Excel-14 Microcatheter, Engineered for GDC Coil Delivery,” 1998.
Boston Scientific, “Tracker Excel-14 Microcatheter, Neurovascular Access,” 2004.
Boston Scientific, “Transend Guidewires, Neurovascular Access,” 2003.
Braley et al., “Advancements in Braided Materials Technology,” 46th Int'l SAMPLE Symposium, May 2001, pp. 2445-2454.
Chestnut Medical Technologies, Inc., “Instructions for Use (IFU), Alligator Retrieval Device (ARD),” 2005.
Concentric Medical, “Instructions for Use, Concentric Micro Catheters”, 2003.
Concentric Medical, “Instructions for Use, Merci Retriever X5IX6,” 2004.
Cordis Corporation, “Cordis CarotidSystem, Cordis Precise Nitinol Self-Expanding Stent and Cordis ANGIOGUARD Emboli Capture Guidewire System,” 2004.
Cordis Corporation, “Cordis CarotidSystem, Technical Specification and Product Codes,” 2006.
Cordis Corporation, “Cordis CarotidSystem RX, Technical Specifications and Product Codes,” 2007.
Cordis Endovascular, “Diagnosing Carotid Artery Disease: The Leading Cause of Stroke,” Sample News Article #1: “Diagnosis,” 2008 or earlier.
Embo Shield, “Xact, Customized for Carotid Arteries, The Barewaire Revolution is Here,” 2005.
Ev3, “ev3 Carotid Innovations, Redefining Confidence, See what you've been missing . . . ”, ev3 The Endovascular Company, 2008 or earlier.
Furlan et al., “Intra-arterial Prourokinase for Acute Ischemic Stroke, The PROCT II Study: A Randomized Controlled Trial,” JAMA, Dec. 1, 1999, vol. 282, Issue 21, pp. 2003-2011.
Henkes et al., “A New Device for Endovascular Coil Retrieval from Intracranial Vessels: Alligator Retrieval Device”, AJRN Am J. Neuroradiol, Feb. 2006, vol. 27, pp. 327-329.
Micro Therapeutics, Inc., “Mirage .008 Hydrophilic Guidewire”, 2000.
Micrus Endovascular, “WATUSI guidewire, Let's Dance,” 2006.
Rymer et al., “Organizing regional networks to increase acute stroke intervention”, Neurological Research, 2005, vol. 27, Issue 1, pp. S9-S16.
Sarti et al., “International Trends in Mortality From Stroke, 1968 to 1994”, http://stroke.ahajournals.org/, American Heart Association, Inc., Apr. 20, 2000, pp. 1588-1601.
University of Minnesota, “Design of Medical Devices Conference,” Apr. 17-19, 2007.
Yadav, “Carotid stenting in high-risk patients: Design and rationale of the SAPPHIRE trial”, Cleveland Clinic Journal of Medicine, Jan. 2004, vol. 71, Issue 1, pp. S45-S46.
Yadav et al., “Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk Patients,” The New England Journal of Medicine, Oct. 7, 2004, vol. 351, Issue 15, pp. 1493-1501 & 1565-1567.
U.S. Appl. No. 60/980,736, filed Oct. 17, 2007.
U.S. Appl. No. 61/044,392, filed Apr. 11, 2008.
U.S. Appl. No. 61/015,154, filed Dec. 19, 2007.
U.S. Appl. No. 60/989,422, filed Nov. 20, 2007.
U.S. Appl. No. 61/019,506, filed Jan. 7, 2008.
U.S. Appl. No. 60/987,384, filed Nov. 12, 2007.
U.S. Appl. No. 61/129,823, filed Jul. 22, 2008.
U.S. Appl. No. 61/202,612, filed Mar. 18, 2009.
U.S. Appl. No. 14/709,794, filed May 12, 2015, Distal Embolic Protection Devices and Mehods for Their Use.
U.S. Appl. No. 14/551,337, filed Nov. 24. 2014, Free End Vascular Treatment Systems.
U.S. Appl. No. 14/013,421, filed Aug. 29, 2013, Laser Cutting Systems.
U.S. Appl. No. 14/013,448, filed Aug. 29, 2013, Woven Vascular Device End Treatments.
U.S. Appl. No. 14/224,637, filed Mar. 25, 2014, Variably Heat-Treated Tubular Devices.
U.S. Appl. No. 14/225,055, filed Mar. 25, 2014, Reversibly Coupled Joints.
U.S. Appl. No. 14/269,594, filed May 5, 2014, Aspiration Catheters.
U.S. Appl. No. 14/926,980, filed Oct. 29, 2015, Variably Bulbous Vascular Treatment Devices.
U.S. Appl. No. 15/085,083, filed Mar. 30, 2016, Longitudinally Variable Vascular Treatment Devices.
U.S. Appl. No. 15/457,089, filed Mar. 13, 2017, Vascular Treatment Devices.
Related Publications (1)
Number Date Country
20160045211 A1 Feb 2016 US
Provisional Applications (1)
Number Date Country
61798540 Mar 2013 US
Continuations (2)
Number Date Country
Parent 14012161 Aug 2013 US
Child 14926636 US
Parent 13952982 Jul 2013 US
Child 14012161 US